• Home
  • About KinaseCentral

Kinase News

Entries RSS | Comments RSS
  • Blogroll

    • CrimsonCanary.com
    • KinaseCentral
    • PharmaCompanyPipelines
  • Tags

    AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
  • Providing a resource for information on kinase inhibitors

ImClone initiate Phase II trial of IMC-1121B in ovarian cancer

Posted on September 30, 2008 by crimsoncanary

ImClone have initiated a phase II clinical trial of VEGFR-2 MAb IMC-1121B in patients with advanced ovarian cancer.

Filed under: Uncategorized | Tagged: IMC-1121B, IMC1121B, ImClone, Monoclonal, VEGFR2

« Regeneron/Bayers VEGF Trap eye shows efficacy in AMD Alcon prepare to initate Phase I trial of Seliciclib for Glaucoma »
  • Calendar

    • September 2008
      M T W T F S S
      « Aug   Oct »
      1234567
      891011121314
      15161718192021
      22232425262728
      2930  
  • Blogroll

    • CrimsonCanary.com
    • KinaseCentral
    • PharmaCompanyPipelines

Blog at WordPress.com. Theme: Digg 3 Column by WP Designer